Medically reviewed by Michael Menna, DO Complement 3 glomerulopathy is a rare disease caused by a buildup of proteins in the ...

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, ...

Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

Iptacopan treatment on top of standard of care resulted in significant and clinically meaningful reductions in proteinuria compared with placebo in patients with complement 3 glomerulopathy. Results ...

The investigational drug avacopan, an oral inhibitor of complement activation, showed meaningful clinical activity in the treatment of C3 glomerulopathy, indicates the largest study ever done in this ...

The results of a newly reported study may offer scientists a strategy for mitigating the negative side effects associated with intravenous injection of nanoparticles used in medicine. The new approach ...

Nanomedicine shows great promise in drug delivery due to its versatility in drug loading and ability to target the tissue of interest; however, its current applicability is significantly hindered by ...

Scientists studied two complement components that are important parts of the immune system and are linked to schizophrenia and autoimmune disorders. They studied the link between two protein ...

EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults ...